The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target

Abstract

In the largest study of its kind to date, these results illustrate the complex relationship between the tumor-immune interaction, prognosis, and response to radiotherapy, and nominate PD-L2 as a potential novel therapeutic target in prostate cancer, potentially in combination with radiotherapy.